Annals of Medicine and Surgery
2026
Sana Rasheed, Rida Arif, Ahmed Asad Raza et al.
1 citation
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory...
World journal of microbiology & biotechnology
December 31, 2025
José Islas-Vargas, Silvia Armenta, Ángeles Alitzel Rivera-Román et al.
2 citations
Psilocybin, a tryptamine-derived alkaloid from Psilocybe mushrooms, has emerged as a high-value biopharmaceutical candidate due to its promising applications in mental health. While clinical studies highlight its rapid and sustained antidepressant effects, current challenges lie in achieving scalable, reproducible, and cost-effective production to meet growing research and therapeutic demand....
Journal of Clinical Medicine
December 29, 2025
Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al.
2 citations
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...
Psychedelic Medicine
December 23, 2025
Anthony L. Back, Bonnie A. Mcgregor, Lindsay Billingsley et al.
1 citation
Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community. Purpose: This technical report describes a group facilitation model developed for an food and drug administration...
JPMA. The Journal of the Pakistan Medical Association
December 20, 2025
Maria Rasool, Taha Hannan, Muhammad Imam
Dear Editor, In view of ongoing global research on mental health, especially Major Depressive Disorder, we would like to draw attention to a psychedelic substance, Psilocybin, which has been emerging as a viable treatment option for MDD. Psilocybin is a psychedelic compound derived from certain mushrooms that acts on Serotonergic receptors (primarily 5HT-2A). Psychedelic substances have...
Irish Journal of Psychological Medicine
December 18, 2025
Gurjot Brar, T. R. Jun. Burke, Andrew Gribben et al.
Abstract Objectives: Interest in psilocybin as a treatment for depression has risen over the past decade, fuelled by promising clinical trials and a rapidly evolving regulatory landscape. Media coverage plays a critical role in shaping public perceptions, yet little is known about how psilocybin is portrayed in global anglophone online news for the treatment of depression. Methods: This study...
Journal of Affective Disorders
December 17, 2025
Faheem Ahmed Khan, Nuruliarizki Shinta Pandupuspitasari, Tewin Tencomnao et al.
2 citations
Psilocybin, a naturally occurring hallucinogenic substance present in certain mushrooms, has drawn growing attention as a therapeutic breakthrough for several mental and psychiatric conditions. Psilocybin originated in spiritual and cultural traditions and has become the focus of extensive scientific research. This meta-analysis and systematic review aggregate results from the literature to...
Journal of Complementary and Alternative Medical Research
December 16, 2025
Shannon Antoine-Hardy, Dennisse Bonilla
Introduction: Major depressive disorder (MDD) affects over 21 million adults in the U.S (NIMH, 2023) and remains a significant public health challenge. Despite the effectiveness of traditional medications, 30% of patients remains resistant. Little is known about the beliefs individuals hold regarding novel treatments, such as psilocybin and the motivations behind medication acceptance. This...
December 15, 2025
Lindsey Elise Wade
Depression is one of the most prevalent and burdensome mental health conditions worldwide, affecting millions and contributing to over 700,000 deaths by suicide annually. Nearly half of patients with major depressive disorder fail to respond adequately to standard antidepressant treatments such as selective serotonin reuptake inhibitors (SSRIs). Psilocybin-assisted therapy (PAT) has emerged as...
DELOS Desarrollo Local Sostenible
December 11, 2025
Pedro Rodrigues, Weliton Rodrigues Dos Santos Júnior, Ivan de Sousa Araújo et al.
Objective: To compare acceptability and effectiveness of psilocybin, ketamine and commonly prescribed antidepressants in the management of Major Depressive Disorder (MDD). Methods: This is a systematic review with network meta-analysis. The survey was conducted between January and June 2023, employing MEDLINE, PsyINFO, Embase, Web of Science and ClinicalTrials.gov databases. Randomized...